节点文献

2型糖尿病2种胰岛素治疗方案的经济学分析

Economic Analysis of 2 kinds of Insulin Treatment for Type 2 Diabetes

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 陈婉纯陈东虹

【Author】 CHEN Wanchun;CHEN Donghong;The People’s Hospital of Jieyang;

【机构】 广东省揭阳市人民医院

【摘要】 目的探讨临床常用的2种胰岛素治疗方案的临床效果和经济效果。方法将116例2型糖尿病患者根据用药平均分成A、B组,分别给予重组甘精胰岛素注射液+门冬胰岛素30注射液、精蛋白重组人胰岛素混合注射液70/30治疗,并进行经济学分析。结果 A、B组的达标住院总成本分别为528.95元和1 123.62元;达标率分别为94.83%和81.03%;成本-效果比分别为5.58和13.87。结论重组甘精胰岛素注射液+门冬胰岛素30注射液治疗2型糖尿病的成本-效果优于精蛋白重组人胰岛素混合注射液70/30。

【Abstract】 OBJECTIVE To investigate the clinical and economic effects of 2 kinds of insulin therapy.METHODS A total of 116 type 2 diabetes patients were divided equally into group A and B based on their different medication,by giving recombinant insulin injection 30+Insulin aspart 30 injection or protamine 70/30 mixed recombinant human insulin injection treatment,respectively.Meanwhile the economic analysis was valued on both groups.RESULTS Total cost of patients reach compliance in the hospital in group A and B was 528.95 yuan and 1 123.62 yuan,respectively.The compliance rate was 94.83% and 81.03%,respectively.Costeffectiveness ratio was 5.58 and 13.87,respectively.CONCLUSION Cost-effectiveness of recombinant Gan insulin glargine injection plus insulin aspart 30 injection treatment for type 2 diabetes is better than that of premixed protamine pecombinant human insulin injection 70/30 treatment.

  • 【文献出处】 今日药学 ,Pharmacy Today , 编辑部邮箱 ,2016年02期
  • 【分类号】R587.1
  • 【被引频次】1
  • 【下载频次】95
节点文献中: